<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<html>
<head>
<title></title>
</head>
<body link="#0000ff" vlink="#7f007f">
<p align="CENTER"><b><font size="5">UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</font>Washington, D.C. 20549</b></p>

<p align="CENTER"><b><font size="5">FORM 8-K</font></b></p>

<p align="CENTER"><b><font size="5">CURRENT REPORT</font><br>
</b>__________________________________________</p>

<p align="CENTER">Pursuant to Section 13 or 15 (d) of<br>
The Securities Exchange Act of 1934</p>

<p align="CENTER"><b>December 13, 2006</b><br>
Date of report (date of earliest event reported)</p>

<p align="CENTER"><b><u><font size=
"5">&nbsp;&nbsp;&nbsp;&nbsp;FOREST LABORATORIES,
INC.&nbsp;&nbsp;&nbsp;&nbsp;<br>
</font></u></b> (Exact name of registrant as specified in its
charter)</p>

<center>
<table cellspacing="0" border="0" width="562">
<tr>
<td width="44%" valign="TOP">
<p align="CENTER"><b>Delaware<br>
</b><i>(State or other jurisdiction of<br>
incorporation or organization)</i></p>
</td>
<td width="18%" valign="TOP">
<p align="CENTER"><b>1-5438<br>
</b>(Commission<br>
 File Number)</p>
</td>
<td width="38%" valign="TOP">
<p align="CENTER"><b>11-1798614<br>
</b><i>(I.R.S. Employer<br>
Identification Number)</i></p>
</td>
</tr>

<tr>
<td width="44%" valign="TOP">&nbsp;</td>
<td width="18%" valign="TOP">&nbsp;</td>
<td width="38%" valign="TOP">&nbsp;</td>
</tr>

<tr>
<td width="44%" valign="TOP">
<p align="CENTER"><b>909 Third Avenue<br>
New York, New York<br>
</b> <i>(Address of principal executive offices)</i></p>
</td>
<td width="18%" valign="TOP">
<p>&nbsp;</p>
</td>
<td width="38%" valign="TOP">
<p align="CENTER"><b>10022-4731<br>
</b><i>(Zip code)</i></p>
</td>
</tr>
</table>
</center>

<p align="CENTER"><b>(212) 421-7850<br>
</b><i>(Registrant&rsquo;s telephone number, including area
code)</i> <u><br>
<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>

</u> <i>(Former name or former address, if changed since last
report)<br>
</i></p>

<p><i>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:</i></p>

<p><font size="3">[&nbsp;]&nbsp;&nbsp;Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))<br>
[&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<i><br>
</i></font></p>

<p align="JUSTIFY">&nbsp;</p>

<p><b>Item 1.01&nbsp;&nbsp;<u>Entry into a Material Definitive
Agreement</u></b></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December 13, 2006, Forest Laboratories, Inc., a Delaware
corporation ("Forest") and its wholly-owned subsidiary, FL
Acquisition Corp., a Delaware corporation, ("Merger Sub") entered
into an Agreement and Plan of Merger (the "Merger Agreement") with
Cerexa, Inc., a Delaware Corporation ("Cerexa"), and Dennis
Podlesak and Eckard Weber, M.D., as the agent (the
"Stockholders&rsquo; Agent") of Cerexa&rsquo;s stockholders (the
"Former Stockholders"), as announced in the attached press release.
Pursuant to the terms and subject to the conditions set forth in
the Merger Agreement, Merger Sub will merge with and into Cerexa
(the "Merger"), and Cerexa will continue as the surviving company
in the Merger as a direct wholly owned subsidiary of Forest. The
Board of Directors of Forest approved the Merger on December 11,
2006.</p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the
terms of the Merger Agreement, upon consummation of the Merger (the
"Effective Time"), Forest will acquire all of the outstanding
capital stock of Cerexa in exchange for aggregate consideration of
(i) $480 million in cash, (ii) assumption of $13.6 million in
expenses and payments related to the transaction and (iii) a
contingent payment of $100 million if U.S net sales of ceftaroline
products during any twelve-month period within the first five years
following the first product launch exceed $500 million. Cerexa has
rights to commercialize ceftaroline, a next generation
broad-spectrum hospital based cephalosporin antibiotic which is
entering Phase III Studies, pursuant to a license with Takeda
Pharmaceutical Company Ltd. Pursuant to the Merger, Forest will
also acquire development and marketing rights (excluding Japan and
certain Asian countries) to another injectable antibiotic and an
option to a third, early stage injectable antibiotic.</p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An escrow
will be established containing 7.5% of the cash consideration,
subject to certain adjustments, and will be maintained for twelve
months following the closing to secure the purchase price
adjustments and the indemnity obligations of the Former
Stockholders under the Merger Agreement.</p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Merger
Agreement contains customary representations, warranties and
covenants, including, in the case of Cerexa, covenants to conduct
its business in the ordinary course consistent with past practice
during the interim period between execution of the Merger Agreement
and the Effective Time of the Merger.</p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completion
of the Merger is subject to the following principal conditions: (i)
no legal or regulatory restraint or prohibition preventing the
consummation of the Merger, (ii) expiration or termination of the
applicable Hart-Scott-Rodino Act waiting period, and (iii) the
absence of any material adverse change affecting Cerexa. Following
execution of the Agreement, the Merger was approved by the
stockholders of Cerexa.</p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
summary of the agreement set forth above is qualified in its
entirety by the agreement, which will be filed as an exhibit to the
Company&rsquo;s quarterly report on Form 10-Q for the period ended
December 31, 2006.</p>

<p>A copy of the press release announcing Forest&rsquo;s entry into
the Merger Agreement is attached to this Current Report as Exhibit
99 and is incorporated herein by reference.</p>

<p><b>Item 9.01&nbsp;&nbsp;<u>Financial Statements and
Exhibits</u></b></p>

<p>Exhibit 99.&nbsp;Press release of Forest Laboratories, Inc.
dated December 14, 2006.</p>

<p align="CENTER"><font face="Courier"><a name=
"Quick_Links"></a></font></p>

<p align="CENTER"><a name="STATEMENTS_OF_INCOME"></a>
SIGNATURES</p>

<p align="JUSTIFY">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly
authorized.</p>

<p align="JUSTIFY">Date: December 19, 2006</p>

<p align="JUSTIFY"><br>
<br>
</p>

<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><u>Forest Laboratories, Inc.</u><br>
(Registrant)</p>

<p align="JUSTIFY"><br>
</p>

<p><u>/s/ Francis I. Perier,
Jr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>

</u> Francis I. Perier, Jr.<br>
Senior Vice President &ndash; Finance and<br>
Chief Financial Officer</p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>

<p><a name="STATEMENTS_OF_COMPREHENSIVE_INCOME"></a></p>

<p><i>&nbsp;</i></p>

 <font face="Courier"></font>
<p align="RIGHT"><font face="Courier">&nbsp;</font></p>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "forest8kdec06cerexa.htm", "description": "FOREST LABORATORIES, INC. 8-K DECEMBER 19, 2006", "secsgml_size_bytes": 8229}]
{"company-data": {"conformed-name": "FOREST LABORATORIES INC", "cik": "0000038074", "assigned-sic": "2834", "irs-number": "111798614", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-05438", "film-number": "061286071"}, "business-address": {"street1": "909 THIRD AVENUE", "city": "NEW YORK", "state": "NY", "zip": "10022", "phone": "(212)421-7850"}, "mail-address": {"street1": "909 THIRD AVENUE", "city": "NEW YORK", "state": "NY", "zip": "10022"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
__________________________________________
Pursuant to Section 13 or 15 (d) of
The Securities Exchange Act of 1934
December 13, 2006
Date of report (date of earliest event reported)
FOREST LABORATORIES,
INC.
(Exact name of registrant as specified in its
charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
1-5438
(Commission
File Number)
11-1798614
(I.R.S. Employer
Identification Number)
909 Third Avenue
New York, New York
(Address of principal executive offices)
10022-4731
(Zip code)
(212) 421-7850
(Registrant's telephone number, including area
code)
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ]  Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]  Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
[ ]  Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
[ ]  Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive
Agreement
On
December 13, 2006, Forest Laboratories, Inc., a Delaware
corporation ("Forest") and its wholly-owned subsidiary, FL
Acquisition Corp., a Delaware corporation, ("Merger Sub") entered
into an Agreement and Plan of Merger (the "Merger Agreement") with
Cerexa, Inc., a Delaware Corporation ("Cerexa"), and Dennis
Podlesak and Eckard Weber, M.D., as the agent (the
"Stockholders' Agent") of Cerexa's stockholders (the
"Former Stockholders"), as announced in the attached press release.
Pursuant to the terms and subject to the conditions set forth in
the Merger Agreement, Merger Sub will merge with and into Cerexa
(the "Merger"), and Cerexa will continue as the surviving company
in the Merger as a direct wholly owned subsidiary of Forest. The
Board of Directors of Forest approved the Merger on December 11,
2006.
Under the
terms of the Merger Agreement, upon consummation of the Merger (the
"Effective Time"), Forest will acquire all of the outstanding
capital stock of Cerexa in exchange for aggregate consideration of
(i) $480 million in cash, (ii) assumption of $13.6 million in
expenses and payments related to the transaction and (iii) a
contingent payment of $100 million if U.S net sales of ceftaroline
products during any twelve-month period within the first five years
following the first product launch exceed $500 million. Cerexa has
rights to commercialize ceftaroline, a next generation
broad-spectrum hospital based cephalosporin antibiotic which is
entering Phase III Studies, pursuant to a license with Takeda
Pharmaceutical Company Ltd. Pursuant to the Merger, Forest will
also acquire development and marketing rights (excluding Japan and
certain Asian countries) to another injectable antibiotic and an
option to a third, early stage injectable antibiotic.
An escrow
will be established containing 7.5% of the cash consideration,
subject to certain adjustments, and will be maintained for twelve
months following the closing to secure the purchase price
adjustments and the indemnity obligations of the Former
Stockholders under the Merger Agreement.
The Merger
Agreement contains customary representations, warranties and
covenants, including, in the case of Cerexa, covenants to conduct
its business in the ordinary course consistent with past practice
during the interim period between execution of the Merger Agreement
and the Effective Time of the Merger.
Completion
of the Merger is subject to the following principal conditions: (i)
no legal or regulatory restraint or prohibition preventing the
consummation of the Merger, (ii) expiration or termination of the
applicable Hart-Scott-Rodino Act waiting period, and (iii) the
absence of any material adverse change affecting Cerexa. Following
execution of the Agreement, the Merger was approved by the
stockholders of Cerexa.
The
summary of the agreement set forth above is qualified in its
entirety by the agreement, which will be filed as an exhibit to the
Company's quarterly report on Form 10-Q for the period ended
December 31, 2006.
A copy of the press release announcing Forest's entry into
the Merger Agreement is attached to this Current Report as Exhibit
99 and is incorporated herein by reference.
Item 9.01
Financial Statements and
Exhibits
Exhibit 99. Press release of Forest Laboratories, Inc.
dated December 14, 2006.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly
authorized.
Date: December 19, 2006
Forest Laboratories, Inc.
(Registrant)
/s/ Francis I. Perier,
Jr.
Francis I. Perier, Jr.
Senior Vice President – Finance and
Chief Financial Officer